By PPN News Staff
The FDA approved fremanezumab-vfrm (Ajovy, Teva) injection for the prevention of migraine in adults.
Fremanezumab-vfrm, a humanized monoclonal antibody that binds to calcitonin gene–related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly (675 mg) and monthly (225 mg) dosing options, which are available in prefilled syringes. Fremanezumab-vfrm can be administered in